Boris Hansel, MD, PhD A statement from the European Medicines Agency (EMA) about semaglutide and, more generally, glucagon-like peptide 1 (GLP-1) agonists recently caused a stir. Could these medicines lead to patients taking their own lives? Medical Authorities AlertThe EMA published a press release in early July 2023 to announce that a review is underway...
Tag: <span>agonists</span>
Post
GLP-1 agonists: Could they be more than just a treatment for diabetes?
High-profile coverage of the off-label use of Ozempic, a GLP-1 agonist, for weight loss, has meant that the type 2 diabetes drug has received a lot of bad press. As more studies into the long-term impact of this group of drugs are published, other potential benefits of the drug are emerging. Glucagon-like peptide-1 (GLP-1) agonist...